Truist analyst Joon Lee raised the firm’s price target on Wave Life Sciences (WVE) to $36 from $17 and keeps a Buy rating on the shares.

Analyst Joon Lee of Truist Financial maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of ...

In-shoe sensors, AI and biomarkers will monitor muscular dystrophy and atrophy in children, adolescents and adults — with ...

ALS is a progressive neurodegenerative disease that affects the function of motor neurons ... SMN dysfunction is implicated ...

Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position ...

The dystrophin expression was quantified from two isoforms consistent with those observed in Duchenne muscular dystrophy ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

There is no shortage of ASX healthcare companies with upcoming catalysts – a focal point for investors. ... Read More The ...

TORONTO, November 13, 2024--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that the Company is scheduled ...